NovoCure Limited (NASDAQ:NVCR) Given Consensus Rating of "Hold" by Analysts

Key Points

• Consensus "Hold": Seven analysts average a Hold rating on NovoCure (1 sell, 3 hold, 3 buy) with a 12‑month consensus price target of about $26.93.
• Insider selling: Insiders, including CFO Christoph Brackmann and Uri Weinberg, sold a combined 140,041 shares (~$1.86M) over the last quarter; insiders now own 5.52% of the stock.
• Mixed fundamentals and stock level: NovoCure beat EPS expectations last quarter (‑$0.22 vs. estimate ‑$0.41) with revenue roughly inline at $174.35M, but remains unprofitable (net margin ‑20.79%) and trades around $12.47 (1‑yr range $9.82–$20.06, market cap ≈ $1.44B).

Shares of NovoCure Limited (NASDAQ:NVCR - Get Free Report) have received an average rating of "Hold" from the seven ratings firms that are currently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and three have assigned a buy recommendation to the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $26.9286.

NVCR has been the subject of several recent research reports. HC Wainwright lifted their target price on shares of NovoCure from $47.00 to $49.00 and gave the company a "buy" rating in a report on Thursday, February 26th. Evercore set a $20.00 price target on shares of NovoCure in a research note on Monday, January 5th. Wedbush reissued a "neutral" rating and issued a $18.00 price target on shares of NovoCure in a research note on Thursday, April 16th. Finally, Weiss Ratings reiterated a "sell (e+)" rating on shares of NovoCure in a research report on Tuesday.

Insiders Place Their Bets

In other news, CFO Christoph Brackmann sold 6,412 shares of NovoCure stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $13.31, for a total value of $85,343.72. Following the sale, the chief financial officer owned 182,842 shares in the company, valued at $2,433,627.02. This trade represents a 3.39% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Uri Weinberg sold 6,412 shares of NovoCure stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $13.31, for a total transaction of $85,343.72. Following the completion of the sale, the insider owned 267,190 shares in the company, valued at approximately $3,556,298.90. This trade represents a 2.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 140,041 shares of company stock valued at $1,860,116. 5.52% of the stock is owned by company insiders.

Institutional Trading of NovoCure

Institutional investors have recently modified their holdings of the stock. Quantbot Technologies LP lifted its holdings in NovoCure by 163.6% in the 3rd quarter. Quantbot Technologies LP now owns 195,515 shares of the medical equipment provider's stock valued at $2,526,000 after purchasing an additional 121,354 shares in the last quarter. Algert Global LLC grew its stake in NovoCure by 372.2% during the 3rd quarter. Algert Global LLC now owns 682,858 shares of the medical equipment provider's stock valued at $8,823,000 after acquiring an additional 538,235 shares in the last quarter. Tudor Investment Corp ET AL grew its stake in NovoCure by 140.6% during the 3rd quarter. Tudor Investment Corp ET AL now owns 606,070 shares of the medical equipment provider's stock valued at $7,830,000 after acquiring an additional 354,216 shares in the last quarter. JPMorgan Chase & Co. grew its stake in NovoCure by 104.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 282,184 shares of the medical equipment provider's stock valued at $3,646,000 after acquiring an additional 144,024 shares in the last quarter. Finally, American Century Companies Inc. grew its stake in NovoCure by 18.3% during the 3rd quarter. American Century Companies Inc. now owns 1,218,807 shares of the medical equipment provider's stock valued at $15,747,000 after acquiring an additional 188,933 shares in the last quarter. Institutional investors and hedge funds own 84.61% of the company's stock.

NovoCure Price Performance

NASDAQ:NVCR opened at $12.47 on Friday. The company has a debt-to-equity ratio of 0.70, a current ratio of 2.90 and a quick ratio of 2.71. The firm has a market cap of $1.44 billion, a price-to-earnings ratio of -10.22 and a beta of 0.82. The company has a 50 day moving average price of $11.97 and a 200-day moving average price of $12.49. NovoCure has a 1-year low of $9.82 and a 1-year high of $20.06.

NovoCure (NASDAQ:NVCR - Get Free Report) last posted its earnings results on Thursday, February 26th. The medical equipment provider reported ($0.22) earnings per share for the quarter, beating the consensus estimate of ($0.41) by $0.19. The firm had revenue of $174.35 million during the quarter, compared to analyst estimates of $174.40 million. NovoCure had a negative net margin of 20.79% and a negative return on equity of 39.11%. The business's quarterly revenue was up 8.2% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.61) EPS. Equities research analysts forecast that NovoCure will post -1.51 EPS for the current year.

About NovoCure

NovoCure is a global oncology company pioneering Tumor Treating Fields (TTFields), a novel anti-mitotic therapy for solid tumors. The company's non-invasive treatment platforms deliver low-intensity, alternating electric fields designed to disrupt cancer cell division. NovoCure's approach offers an alternative modality to complement existing therapies in oncology, with a focus on hard-to-treat malignancies.

Founded in 2000 and headquartered in Haifa, Israel, NovoCure maintains a second operational center in Portsmouth, New Hampshire.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.